AstraZeneca on Thursday said its experimental drug tezepelumab had been given a priority review by the US Food and Drug Administration for potential approval as a treatment for asthma.
The medicine, developed in conjunction with US-based Amgen, showed in trials it can reduce asthma attacks in patients with severe and uncontrolled forms of the respiratory condition.
A decision is expected in the first quarter of 2022, the company said on Thursday.
